Published in Cell Mol Gastroenterol Hepatol on June 17, 2015
The CMGH Awards. Cell Mol Gastroenterol Hepatol (2017) 0.75
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Circos: an information aesthetic for comparative genomics. Genome Res (2009) 40.02
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med (2014) 4.98
Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet (2012) 4.84
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med (2012) 3.92
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88
Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res (2009) 3.41
Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem (2012) 3.35
Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res (2007) 2.88
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol (2009) 2.69
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol (2009) 2.53
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 2.38
K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol (1999) 1.53
The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways. Oncogene (2010) 1.45
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer (2010) 1.22
Targeted therapy of hepatocellular carcinoma: present and future. J Gastroenterol Hepatol (2012) 1.21
A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol (2011) 1.17
Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer (2011) 1.05
Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Clin Cancer Res (2000) 1.00
Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. Lung Cancer (2013) 0.93
Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanoma. Cancer Med (2013) 0.84
Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol (2013) 0.83
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet (2014) 2.72
Novel genetic markers associate with atrial fibrillation risk in Europeans and Japanese. J Am Coll Cardiol (2014) 1.86
Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population. Gastroenterology (2016) 1.62
Mutational signatures associated with tobacco smoking in human cancer. Science (2016) 1.58
High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry. Nat Genet (2016) 1.09
Construction of a population-specific HLA imputation reference panel and its application to Graves' disease risk in Japanese. Nat Genet (2015) 1.02
Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet (2016) 1.02
Multiple nonglycemic genomic loci are newly associated with blood level of glycated hemoglobin in East Asians. Diabetes (2014) 0.93
Integrated Multiregional Analysis Proposing a New Model of Colorectal Cancer Evolution. PLoS Genet (2016) 0.92
Performance comparison of four commercial human whole-exome capture platforms. Sci Rep (2015) 0.89
Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. Hum Mol Genet (2016) 0.87
A combination of targeted enrichment methodologies for whole-exome sequencing reveals novel pathogenic mutations. Sci Rep (2015) 0.87
Identification of a p53-repressed gene module in breast cancer cells. Oncotarget (2017) 0.86
Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. Hum Mol Genet (2015) 0.85
Exome Analyses of Long QT Syndrome Reveal Candidate Pathogenic Mutations in Calmodulin-Interacting Genes. PLoS One (2015) 0.85
The construction of risk prediction models using GWAS data and its application to a type 2 diabetes prospective cohort. PLoS One (2014) 0.83
A deletion mutation in myosin heavy chain 11 causing familial thoracic aortic dissection in two Japanese pedigrees. Int J Cardiol (2015) 0.82
Trans-ethnic meta-analysis of white blood cell phenotypes. Hum Mol Genet (2014) 0.82
Genome-Wide Association Study of Peripheral Arterial Disease in a Japanese Population. PLoS One (2015) 0.80
A genome-wide association study to identify genomic modulators of rate control therapy in patients with atrial fibrillation. Am J Cardiol (2014) 0.79
ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population. BMC Genet (2016) 0.78
TUBA1A mutation can cause a hydranencephaly-like severe form of cortical dysgenesis. Sci Rep (2015) 0.78
The Transcriptional Landscape of p53 Signalling Pathway. EBioMedicine (2017) 0.78
Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nat Genet (2017) 0.77
Genetic Variation in the SLC8A1 Calcium Signaling Pathway Is Associated with Susceptibility to Kawasaki Disease and Coronary Artery Abnormalities. Circ Cardiovasc Genet (2016) 0.76
A Genome Wide Study of Copy Number Variation Associated with Nasopharyngeal Carcinoma in Malaysian Chinese Identifies CNVs at 11q14.3 and 6p21.3 as Candidate Loci. PLoS One (2016) 0.76
Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors. Oncoimmunology (2017) 0.75
Polygenic burdens on cell-specific pathways underlie the risk of rheumatoid arthritis. Nat Genet (2017) 0.75
Gene expression profiling of DBA/2J mice cochleae treated with l-methionine and valproic acid. Genom Data (2015) 0.75
Constitutional abnormalities of IDH1 combined with secondary mutations predispose a patient with Maffucci syndrome to acute lymphoblastic leukemia. Pediatr Blood Cancer (2017) 0.75
miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Gut (2017) 0.75
Clinical utility and functional analysis of variants in atrial fibrillation-associated locus 4q25. J Cardiol (2017) 0.75
Pathogen lineage-based genome-wide association study identified CD53 as susceptible locus in tuberculosis. J Hum Genet (2017) 0.75
Identification of a p53 target, CD137L, that mediates growth suppression and immune response of osteosarcoma cells. Sci Rep (2017) 0.75
Genetic landscape of interactive effects of HLA-DRB1 alleles on susceptibility to ACPA(+) rheumatoid arthritis and ACPA levels in Japanese population. J Med Genet (2017) 0.75
A genome-wide association analysis identifies NMNAT2 and HCP5 as susceptibility loci for Kawasaki disease. J Hum Genet (2017) 0.75